Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-760 plus R-GemOx versus placebo plus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
CTR20243564Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing HMPL-760 + R-GemOx with Placebo + R-GemOx (2 arms). Primary endpoint: Progression-free survival. Started Nov 2024; status: completed.
02
Drugs
HMPL-760
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20243564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243564.